These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2198 related articles for article (PubMed ID: 18001800)

  • 1. Long-term followup results of 1 cycle of adjuvant bleomycin, etoposide and cisplatin chemotherapy for high risk clinical stage I nonseminomatous germ cell tumors of the testis.
    Westermann DH; Schefer H; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
    J Urol; 2008 Jan; 179(1):163-6. PubMed ID: 18001800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term results following adjuvant chemotherapy in patients with clinical stage I testicular nonseminomatous malignant germ cell tumors with high risk factors.
    Böhlen D; Borner M; Sonntag RW; Fey MF; Studer UE
    J Urol; 1999 Apr; 161(4):1148-52. PubMed ID: 10081858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.
    Albers P; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Weissbach L; Loy V; Wittekind C; Hartmann M;
    J Clin Oncol; 2008 Jun; 26(18):2966-72. PubMed ID: 18458040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
    Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
    Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of prognostic factors in the management of stage I nonseminomatous germ cell testicular tumors (NSGCTT).
    Ondrus D; Goncalves F; Kausitz J; Mat'oska J; Belan V
    Neoplasma; 1996; 43(3):195-7. PubMed ID: 8841507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy of two cycles of BEP regimen in high-risk stage I nonseminomatous testicular germ cell tumors with embryonal carcinoma and/or vascular invasion.
    Chevreau C; Mazerolles C; Soulié M; Gaspard MH; Mourey L; Bujan L; Plante P; Rischmann P; Bachaud JM; Malavaud B
    Eur Urol; 2004 Aug; 46(2):209-14; discussion 214-5. PubMed ID: 15245815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are 3 cycles of bleomycin, etoposide and cisplatin or 4 cycles of etoposide and cisplatin equivalent optimal regimens for patients with good risk metastatic germ cell tumors of the testis? The need for a randomized trial.
    Culine S; Theodore C; Terrier-Lacombe MJ; Droz JP
    J Urol; 1997 Mar; 157(3):855-8; discussion 858-9. PubMed ID: 9072585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved management of abdominal undescended testicular tumors with bulky confluent retroperitoneal nodal metastases.
    Kulkarni JN; Desai SM; Phadke GK; Tongaonkar HB
    J Urol; 1996 Oct; 156(4):1341-4. PubMed ID: 8808867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two cycles of carboplatin-based adjuvant chemotherapy for high-risk clinical stage I and stage IM non-seminomatous germ cell tumours of the testis: a HECOG trial.
    Pectasides D; Skarlos D; Dimopoulos AM; Farmakis D; Pectasides M; Fountzilas G; Aravantinos G
    Anticancer Res; 2003; 23(5b):4239-44. PubMed ID: 14666633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program.
    Tandstad T; Dahl O; Cohn-Cedermark G; Cavallin-Stahl E; Stierner U; Solberg A; Langberg C; Bremnes RM; Laurell A; Wijkstrøm H; Klepp O
    J Clin Oncol; 2009 May; 27(13):2122-8. PubMed ID: 19307506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Management of stage I testicular nonseminomatous germ cell tumors with an embryonic carcinomatous component. 18 cases].
    Drianno N; Robert M; Legouffe E; Guiter J; Navratil H
    Prog Urol; 1997 Sep; 7(4):622-7. PubMed ID: 9410322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relapse-free and overall survival in patients with pathologic stage II nonseminomatous germ cell cancer treated with etoposide and cisplatin adjuvant chemotherapy.
    Kondagunta GV; Sheinfeld J; Mazumdar M; Mariani TV; Bajorin D; Bacik J; Bosl GJ; Motzer RJ
    J Clin Oncol; 2004 Feb; 22(3):464-7. PubMed ID: 14752068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin-based chemotherapy after retroperitoneal lymph node dissection in patients with pathological stage II nonseminomatous germ cell tumors.
    Culine S; Theodore C; Farhat F; Bekradda M; Terrier-Lacombe MJ; Droz JP
    J Surg Oncol; 1996 Mar; 61(3):195-8. PubMed ID: 8637206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Results of the German studies (MAHO) for treatment of testicular germ cell tumors in children--an update].
    Schmidt P; Haas RJ; Göbel U; Calaminus G
    Klin Padiatr; 2002; 214(4):167-72. PubMed ID: 12165897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome of patients with clinical stage I high-risk nonseminomatous germ-cell tumors 15 years after one adjuvant cycle of bleomycin, etoposide, and cisplatin chemotherapy.
    Vidal AD; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
    Ann Oncol; 2015 Feb; 26(2):374-7. PubMed ID: 25392157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Urologic treatment of testicular germ cell cancer].
    Fernández Gómez JM; Escaf Barmadah S; Guate Ortiz JL; Martín Huescar A; Fresno Forcelledo F; García Rodríguez J; Rodríguez Faba O; Jalón Monzón A; Rodríguez Martínez JJ
    Arch Esp Urol; 2002 Oct; 55(8):927-36. PubMed ID: 12455283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Report of the long-term efficacy of two cycles of adjuvant bleomycin/etoposide/cisplatin in patients with stage I testicular nonseminomatous germ-cell tumors (NSGCT): a risk adapted protocol of the Hellenic Cooperative Oncology Group.
    Bamias A; Aravantinos G; Kastriotis I; Alivizatos G; Anastasiou I; Christodoulou C; Gyftaki R; Kalofonos HP; Dimopoulos MA
    Urol Oncol; 2011; 29(2):189-93. PubMed ID: 19362863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of surveillance protocol of clinical stage I nonseminomatous germ cell tumors-is shift to risk adapted policy justified?
    Divrik RT; Akdoğan B; Ozen H; Zorlu F
    J Urol; 2006 Oct; 176(4 Pt 1):1424-29; discussion 1429-30. PubMed ID: 16952649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is bleomycin necessary in adjuvant chemotherapy of clinical stage I non-seminomatous testicular cancer?
    Mezvrishvili Z; Managadze L
    Georgian Med News; 2006 May; (134):25-8. PubMed ID: 16783058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment outcome of children and adolescents with germ cell tumor after combined therapy---a report of 44 cases].
    Sun XF; Yang QY; Zhen ZJ; Xia Y; Huang ZH; Ling JY
    Ai Zheng; 2006 Dec; 25(12):1529-32. PubMed ID: 17166380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 110.